Adjuvant Intraperitoneal Gemcitabine for Resectable Pancreatic Adenocarcinoma
Status:
Terminated
Trial end date:
2014-02-01
Target enrollment:
Participant gender:
Summary
This is a phase II study evaluating the use of intraperitoneal gemcitabine given
intraoperatively and as adjuvant therapy for patients with resectable pancreas cancer.
The primary objective of this study is to evaluate the overall safety of intraperitoneal
gemcitabine given intraoperatively and postoperatively for adjuvant treatment of resectable
pancreatic adenocarcinoma.
The secondary objectives are to evaluate the efficacy of this treatment regimen as reflected
in overall survival at 2-years, to study the patterns of disease recurrence following this
treatment, to study the pharmacology of intraperitoneal gemcitabine and to study changes in
peritoneal cytology with pancreatic cancer resection.
Phase:
Phase 2
Details
Lead Sponsor:
Medstar Health Research Institute Washington Hospital Center